100490-99-1

Basic information

• Product Name: Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat
• Synonyms: Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat;Ethyl3-(2,4-Difluoroanilino)-2-(2,6-dichloro-5-fluronicotinoyl)acrylate;2,6-Dichloro-alpha-[[(2,4-difluorophenyl)amino]methylene]-5-fluoro-beta-oxo-3-pyridinepropanoic acid ethyl ester;Ethyl 2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)acrylate;Ethyl 2-(2,6-dichloro-5-fluoropyridin-3-carbonyl)-3-(2,4-difluorphenylamino)acrylate;ethyl 2-(2,6-dichloro-5-fluoronicotinoyl)-3-((2,4-difluorophenyl)amino)acrylate
• CAS NO: 100490-99-1
• Molecular Formula: C₁₇H₁₁Cl₂F₃N₂O₃
• Molecular Weight: 419.18
• Mol File: 100490-99-1.mol

Chemical Properties

• Melting Point: 138-139℃
• Boiling Point: 511.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.510
• PKA: -2.75±0.70(Predicted)
• CAS DataBase Reference: Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat(100490-99-1)
• EPA Substance Registry System: Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat(100490-99-1)

Safety Data

• Hazardous Substances Data: 100490-99-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat is utilized as a potential drug candidate for the treatment of various medical conditions. Its unique molecular structure, which includes fluorine, chlorine, and nitrogen atoms, contributes to its potential therapeutic activity, making it a subject of ongoing research and development in medicinal chemistry.
The specific applications and reasons for its use in the pharmaceutical industry are still under investigation, as the pharmacological and biological properties of Ethyl-2-(2,6-dichlor-5-fluorpyridin-3-carbonyl)-3-(2,4-difluorphenylamino)-acrylat are being explored. Its development as a drug candidate is driven by the need to discover new therapeutic agents that can effectively address a variety of health challenges.

Upstream product

• 367-25-9 2,4-difluorophenylamine 
• 96568-05-7 2,6-dichloro-α-(ethoxymethylene)-5-fluoro-β-oxo-3-pyridinepropanoic acid ethyl ester 
• 96568-04-6 ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxopropanoate 
• 122-51-0 orthoformic acid triethyl ester 
• 96568-02-4 2,6-dichloro-5-fluoro-3-nicotinoyl chloride 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 82671-03-2 ethyl 2,6-dichloro-5-fluoropyridine-3-carboxylate 

Downstream Products

• 104051-69-6 7-(3'-aminopyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 104051-62-9 ethyl 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylate 
• 100492-07-7 1-(2,4-Difluoro-phenyl)-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 100491-63-2 1-(2,4-Difluoro-phenyl)-6-fluoro-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 100491-94-9 ethyl 7-(3-acetylamino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 
• 104051-67-4 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 104051-68-5 1-(2,4-Difluoro-phenyl)-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; hydrochloride 
• 104069-97-8 1-(2,4-Difluoro-phenyl)-6-fluoro-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; hydrochloride 
• 100492-04-4 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 
• 138751-74-3 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid 
• 100491-29-0 ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 

Relevant articles and documents

ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS

Disclosed are guanidine and biguanidine derivatives which have anti-viral and antibacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds. Methods of treating infections using the guanidine and biguanidine derivatives are also disclosed.

Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids

A series of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids have been prepared and tested for their in vitro and in vivo antibacterial activities.The 5-methyl group gave better in vitro activity with the 1-cyclopropyl appendage, but poorer activity with the 1-tert-butyl moiety.With the 1-(2,4-difluorophenyl) substitution, the influence of the 7-cycloalkylamino group was determinant: a (3S)-3-aminopyrrolidine was shown to enhance greatly the in vitro and in vivo activity of the 5-methyl derivative.Compound 33 (BMY 43748) was selec ted as a promising candidate for an improved therapeutic agent.

Synthesis and Structure-Activity Relationships of New Arylfluoronaphthyridine Antibacterial Agents

Novel arylfluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid have been prepared and their antibacterial activity evaluated.These derivatives are characterized by having a fluorine atom at 6-position, substituted amino groups at the 7-position, and substituted phenyl groups at the 1-position.The in vitro antibacterial potency is greatest when the 1-substituent is either p-fluorophenyl or o,p-difluorophenyl and the 7-substituent is a 3-amino-1-pyrrolidinyl group. 1-(2,4-Difluorophenyl)-6-fluoro-7-(3-amino-1-pyrrolidinyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (38) was found to possess excellent in vitro potency and in vivo efficacy.